| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
m-PEG10-alcohol does not target a biological receptor. Its function is as a chemical linker or spacer. The terminal hydroxyl group (-OH) serves as a reactive handle for further chemical derivatization. In the context of ADCs and PROTACs, the PEG10 spacer is used to connect a cytotoxic payload or a protein-targeting ligand to an antibody or an E3 ubiquitin ligase ligand. The methoxy group at the other end is inert and serves to cap the PEG chain, preventing unwanted crosslinking or side reactions.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [1].
As a chemical linker, m-PEG10-alcohol has no intrinsic biological activity. Its utility is defined by its chemical properties. The primary hydroxyl group can be activated or converted into other functional groups (e.g., tosylate, mesylate, amine, or carboxylic acid) to facilitate conjugation. The hydrophilic PEG10 spacer increases the aqueous solubility of the final conjugate and reduces aggregation, which is a common issue with hydrophobic drugs or proteins. Its non-cleavable nature ensures that the linker remains stable in the bloodstream, providing a durable connection between the antibody and the payload in an ADC. |
| ln Vivo |
No direct in vivo activity is attributed to m-PEG10-alcohol. Its biological relevance is derived from its use as a component in biopharmaceuticals like ADCs and PROTACs. In ADCs, the PEG10 spacer helps to improve the pharmacokinetic properties of the conjugate by increasing its solubility and reducing its immunogenicity, which can lead to a longer circulation half-life. In PROTACs, the PEG10 linker provides the appropriate distance and flexibility between the two ligands (the target protein binder and the E3 ligase binder) to facilitate the formation of the ternary complex and subsequent protein degradation.
|
| Enzyme Assay |
For in vitro characterization, m-PEG10-alcohol is typically analyzed by NMR and HPLC to confirm its structure and purity. Purity is often >98%. The compound is a solid at room temperature. Its solubility in various solvents can be determined, as it is important for its use in conjugation reactions. The presence of the hydroxyl group can be confirmed by chemical tests or by derivatization followed by chromatographic analysis.
|
| Cell Assay |
Cell-based assays are not performed on m-PEG10-alcohol itself. As a linker, it is incorporated into larger constructs (ADCs or PROTACs) that are then evaluated in cell culture. For example, an ADC containing the m-PEG10-alcohol linker would be tested for its ability to bind to a target antigen on cancer cells, be internalized, and deliver a cytotoxic payload, leading to cell death. Similarly, a PROTAC containing this linker would be tested for its ability to degrade a target protein.
|
| Animal Protocol |
In vivo studies with m-PEG10-alcohol are conducted using the final conjugate (ADC or PROTAC) rather than the linker alone. These studies typically involve administering the conjugate to animal models, such as tumor-bearing mice, to assess its efficacy and pharmacokinetics. The PEG10 spacer contributes to the overall performance of the conjugate by improving its solubility, stability, and circulation time.
|
| ADME/Pharmacokinetics |
As a linker, m-PEG10-alcohol does not have independent pharmacokinetic (PK) properties. However, the PEG10 spacer is known to impart favorable PK characteristics to the final conjugate. The hydrophilic PEG chain shields the conjugate from recognition by the immune system, reducing opsonization and clearance by the reticuloendothelial system. This results in a prolonged circulation half-life and improved exposure to the target tissue.
|
| Toxicity/Toxicokinetics |
The toxicology of m-PEG10-alcohol is not typically evaluated independently, as it is a component of a larger molecule. However, PEG is generally considered to be biocompatible and non-toxic. The compound itself is classified as a non-cleavable linker, meaning it is not designed to be metabolized or cleaved in the body, which contributes to its stability and low inherent toxicity.
|
| References |
[1]. Nnochiri Ekwuribe, et al. Calcitonin drug-oligomer conjugates, and uses thereof. US20040091452A1.
|
| Additional Infomation |
m-PEG10-alcohol (Decaethylene glycol monomethyl ether) is a monodisperse, non-cleavable PEG linker used in the synthesis of ADCs and PROTACs. It consists of 10 ethylene oxide units, providing a defined spacer length to improve the solubility and stability of bioconjugates. The compound is a valuable tool in drug delivery and targeted therapy research. It is available for research use only and is not a therapeutic agent itself.
|
| Molecular Formula |
C21H44O11
|
|---|---|
| Molecular Weight |
472.5675
|
| Exact Mass |
472.288
|
| CAS # |
27425-92-9
|
| PubChem CID |
14550547
|
| Appearance |
Colorless to light yellow Solid-Liquid Mixture
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
524.3±45.0 °C at 760 mmHg
|
| Melting Point |
19ºC
|
| Flash Point |
270.9±28.7 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.455
|
| LogP |
-4.02
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
29
|
| Heavy Atom Count |
32
|
| Complexity |
324
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])O[H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])[H]
|
| InChi Key |
YMBLPWKGRIGDBP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H44O11/c1-23-4-5-25-8-9-27-12-13-29-16-17-31-20-21-32-19-18-30-15-14-28-11-10-26-7-6-24-3-2-22/h22H,2-21H2,1H3
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1161 mL | 10.5804 mL | 21.1609 mL | |
| 5 mM | 0.4232 mL | 2.1161 mL | 4.2322 mL | |
| 10 mM | 0.2116 mL | 1.0580 mL | 2.1161 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
